Abstract:Purpose: To evaluate the tolerability, safety, pharmacokinetics and drug interaction of cefotaxime sodium–tazobactam sodium injection (6:1) in Chinese healthy subjects. The results of the safety and pharmacokinetic studies supported further clinical trials.Method: A randomized, single-blind, ascending dose, placebo-controlled, single-center study was conducted. Sixty healthy subjects (38 males, 22 females) participated in this study. For the single-dose part, 0.47, 1.17, 2.34, 3.51, and 4.68 g of cefotaxime sodium–tazobactam sodium injection (6:1) was administered. For the multiple-dose part, the subjects were administered 2.34 and 3.51 g cefotaxime sodium–tazobactam sodium injection (6:1) three times a day for 7 consecutive days. For the drug interaction part, the subjects received 2.0 g cefotaxime sodium and 0.34 g tazobactam sodium alone and in combination.Results: Most adverse events and adverse drug reactions were mild. Moderate rash was considered a serious adverse event because of prolongation of hospitalization. The main pharmacokinetic parameters of cefotaxime and tazobactam had no significance difference between the 1.17, 2.34, and 3.51 g dose cohorts and between genders. There was no difference in trough concentrations on days 6, 7, and 8. The RCmax and RAUC were (0.921 ± 0.070) and (0.877 ± 0.057) for cefotaxime, and (0.913 ± 0.046) and (0.853 ± 0.060) for tazobactam, respectively. Following the administration of cefotaxime and tazobactam alone and in combination, the 90% confidence intervals of the geometric mean ratios for Cmax and AUC were within the predetermined range of 80–125%. In the single-dose part, the renal cumulative excretion ratios were (51.7 ± 6.2)% for cefotaxime, and (84.3 ± 8.1)% for tazobactam. There was no significant difference in the maximum excretion rates and cumulative excretion ratios for cefotaxime and tazobactam, alone or in combination.Conclusions: Cefotaxime sodium–tazobactam sodium injection (6:1) was well-tolerated at doses of 0.47 to 4.68 g. The pharmacokinetics of cefotaxime and tazobactam were reported as linear over a dose range of 1.17–3.51 g. Cefotaxime was partially excreted via urine, whereas tazobactam was mainly excreted via urine. There was no significant accumulation after administration over 7 consecutive days. The pharmacokinetics and excretion of cefotaxime and tazobactam were not affected by the co-administration of cefotaxime–tazobactam.

Investigation on the tolerance to cefotaxime/sulbactam in healthy volunteers after a single intravenous infusion administration

Tolerability and Pharmacokinetics of Multiple-Dose Ceftriaxone/Sulbactam (4:1) Injection in Chinese Health Volunteers

Tolerance of single and multiple intravenous infusion ceftazidime/tazobactam (5∶1) in Chinese healthy volunteers

Tolerability, Safety, Pharmacokinetics and Drug Interaction of Cefotaxime Sodium–Tazobactam Sodium Injection (6:1) Following Single and Multiple Intravenous Doses in Chinese Healthy Subjects

Pharmacokinetic Study of Cefotetan Disodium for Injection in Chinese Healthy Volunteers

Pharmacokinetics and tolerability of intravenous cefotetan disodium for injection in healthy Chinese volunteers: A randomized, open-label, single- and multiple-dose study.

Safety and Tolerance of Single-dose Caderofloxacin Lactate Injection in Chinese Healthy Volunteers

A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections

A Single- and Multiple-Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of Ceftolozane/tazobactam in Healthy Chinese Participants

Tolerance of soxifloxacin hydrochloride tablet after ascending single dose in Chinese healthy subjects

Cefoperazone/sulbactam in Treatment of Biliary Tract Infections: A Prospective Multicenter Clinical Trial

A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese Subjects

Pharmacokinetic Study of Cefazedone Sodium Given by Intravenous Drip Infusion in Healthy Volunteers

Multicenter Clinical Study on Piperacillin/Sulbactam for Treatment of Respiratory and Urinary Tract Infection

Tolerance study of ulinastatin injection in Chinese healthy volunteers

Pharmacokinetics study on cefoperazone and tazobactam compound injection in health volunteers

Pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose intravenous ceftobiprole in healthy Chinese participants

Tolerance of Antofloxacin Hydrochloride after Ascending Single Oral Dose Administration in Healthy Male Volunteers

Pharmacokinetic study on piperacillin and sulbactam (4:1) injection in healthy volunteers

A multicenter randomized control clinical trial of cefepime hydrochloride injection in the treatment of acute bacterial infections

A First-in-human Safety, Tolerability and Pharmacokinetics study of Benapenem in Healthy Chinese Volunteers.